Lxr modulators

Abstract

Compounds, pharmaceutically acceptable salts, isomers, or prodrugs thereof, of the invention are disclosed, which are useful as modulators of the activity of liver X receptors (LXR). Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.

We claim: 
     
         1 . A compound selected from the group consisting of 2-(1-(3-chloro-3′-fluoro-4′-(hydroxymethyl)-5′-(methylsulfonyl)biphenyl-4-yl)-2-(2-(2-fluorophenyl)propan-2-yl)-1H-imidazol-4-yl)propan-2-ol and 2-(2-(2-(2-chloro-6-fluorophenyl)propan-2-yl)-1-(3′-fluoro-4′-(hydroxymethyl)-3-methyl-5′-(methylsulfonyl)biphenyl-4-yl)-1H-imidazol-4-yl)propan-2-ol, or isotope, or a pharmaceutically acceptable salt thereof. 
     
     
         2 . The compound of  claim 1 , which is 2-(1-(3-chloro-3′-fluoro-4′-(hydroxymethyl)-5′-(methylsulfonyl)biphenyl-4-yl)-2-(2-(2-fluorophenyl)propan-2-yl)-1H-imidazol-4-yl)propan-2-ol, or isotope, or a pharmaceutically acceptable salt thereof. 
     
     
         3 . The compound of  claim 1 , which is 2-(2-(2-(2-chloro-6-fluorophenyl)propan-2-yl)-1-(3′-fluoro-4′-(hydroxymethyl)-3-methyl-5′-(methylsulfonyl)biphenyl-4-yl)-1H-imidazol-4-yl)propan-2-ol, or isotope, or a pharmaceutically acceptable salt thereof. 
     
     
         4 . A pharmaceutical composition comprising a compound of  claim 1 , or isotope, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers. 
     
     
         5 . A method of treating a disease or disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound of  claim 1 , or isotope, or a pharmaceutically acceptable salt thereof, wherein the disease or disorder is insulin resistance, osteoarthritis, stroke, hyperglycemia, psoriasis, age and UV exposure-related skin wrinkling, diabetes, cancer, Alzheimer's disease, inflammation, immunological disorders, lipid disorders, obesity, macular degeneration, conditions characterized by a perturbed epidermal barrier function, conditions of disturbed differentiation or excess proliferation of the epidermis or mucous membrane, or cardiovascular disorders. 
     
     
         6 . The method of  claim 5 , wherein the disease or disorder is a cardiovascular disorder, a lipid disorder, diabetes, or Alzheimer's disease. 
     
     
         7 . The method of  claim 6 , wherein the disease or disorder is a cardiovascular disorder. 
     
     
         8 . The method of  claim 7 , wherein said cardiovascular disorder is atherosclerosis. 
     
     
         9 . The method of  claim 6 , wherein the disease or disorder is a lipid disorder. 
     
     
         10 . The method of  claim 9 , wherein said lipid disorder is dyslipidemia. 
     
     
         11 . The method of  claim 5  wherein the disease or disorder is diabetes. 
     
     
         12 . The method of  claim 5  wherein the disease or disorder is Alzheimer's disease.